Table 6 (abstract P430). Laboratory features and treatment modalities of the patients
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three
A | B1 | B2 | C1 | C2 | |
|---|---|---|---|---|---|
CH50 | 35% (70-140) | 29% (40-130) | 27% (40-130) | <3 U/ml (30-75) | <3 U/ml (30-75) |
C1q | <6 mg/L (118-238) | 126% (70-130) | 150% (70-130) | Not evaluated | 25 mg/dl (12-22) |
C2 | Not evaluated | Not evaluated | 40 mg/L (14-25) | Not evaluated | 3.1 mg/dl (1.13) |
C3 | 175 mg/dl (90-180) | 104 mg/dl (90-180) | 152 mg/dl (90-180) | 119 mg/dl (90-180) | 95 mg/dl (90-180) |
C4 | 37 mg/dl (10-40) | 31 mg/dl (10-40) | 38 mg/L (10-40) | 30.4 mg/dl (10-40) | 26mg/dl (10-40) |
Prior treatment | Steroid | Steroid | Steroid | Steroid | No treatment |
Azathioprine | Methotrexate | Methotrexate | Azathioprine | ||
Hydroxychloroquine | Hydroxychloroquine | Hydroxychloroquine | Hydroxychloroquine | ||
Present treatment | Hydroxychloroquine | Hydroxychloroquine | Hydroxychloroquine | Hydroxychloroquine | Hydroxychloroquine |
FFP | FFP | FFP | FFP | FFP | |
Time of FFP treatment | 37 months | 28 months | 30 months | 7 months | 7 months |
Frequency of FFP | 3 weekly | 4 weekly | 3 weekly | Once a week | Once a week |